IRIS UniCatt

Bianco, Assunta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.194
EU - Europa 1.838
AS - Asia 1.702
SA - Sud America 344
AF - Africa 36
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.123
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.128
SG - Singapore 777
DE - Germania 663
CN - Cina 391
SE - Svezia 291
BR - Brasile 277
IT - Italia 243
VN - Vietnam 156
FR - Francia 152
GB - Regno Unito 104
UA - Ucraina 89
IE - Irlanda 70
IN - India 70
FI - Finlandia 64
HK - Hong Kong 54
ID - Indonesia 48
BD - Bangladesh 39
JP - Giappone 36
CA - Canada 32
RU - Federazione Russa 29
AR - Argentina 26
TR - Turchia 26
IQ - Iraq 24
PL - Polonia 22
AT - Austria 19
BE - Belgio 18
NL - Olanda 16
KR - Corea 15
MX - Messico 14
CI - Costa d'Avorio 13
VE - Venezuela 13
ES - Italia 9
SA - Arabia Saudita 9
CO - Colombia 8
EC - Ecuador 8
IR - Iran 8
JO - Giordania 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
IL - Israele 5
LT - Lituania 5
PK - Pakistan 5
TN - Tunisia 5
AU - Australia 4
CZ - Repubblica Ceca 4
MA - Marocco 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
CL - Cile 3
HU - Ungheria 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
NO - Norvegia 3
NP - Nepal 3
PA - Panama 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
EE - Estonia 2
EG - Egitto 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KG - Kirghizistan 2
LV - Lettonia 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
SN - Senegal 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
HT - Haiti 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MT - Malta 1
Totale 6.118
Salva come PNG Salva come JPEG
Città #
Singapore 444
Chandler 319
San Jose 249
Ashburn 212
Frankfurt am Main 124
Beijing 85
New York 73
Ann Arbor 71
Dublin 70
Jacksonville 57
San Mateo 57
Los Angeles 55
Hong Kong 53
Nürnberg 51
Hefei 50
Lauterbourg 50
Ho Chi Minh City 49
Rome 48
Jakarta 47
Milan 46
Hanoi 43
Tokyo 31
Boston 29
Munich 29
Nanjing 28
Wilmington 28
São Paulo 26
Princeton 24
Woodbridge 24
Chicago 22
Dearborn 22
Helsinki 22
Santa Clara 22
Dallas 21
Houston 21
Buffalo 20
Moscow 20
Bremen 18
Marseille 18
Atlanta 17
Brussels 17
Nuremberg 17
Kent 16
Seoul 15
Warsaw 15
Izmir 14
Lappeenranta 14
Orem 14
Pune 14
Abidjan 13
Turku 13
Brooklyn 12
The Dalles 12
Baghdad 11
Boardman 11
London 11
Norwalk 11
Seattle 11
Shanghai 11
Cattolica 10
Council Bluffs 10
Lawrence 10
Rio de Janeiro 10
Redwood City 9
Vienna 9
Chennai 8
Denver 8
Düsseldorf 8
Haiphong 8
Leawood 8
North Bergen 8
Toronto 8
Amsterdam 7
Detroit 7
Kunming 7
Montreal 7
Nanchang 7
Thái Nguyên 7
Tianjin 7
Andover 6
Ankara 6
Da Nang 6
Las Vegas 6
Paris 6
Portsmouth 6
San Francisco 6
Tukwila 6
Washington 6
Amman 5
Belo Horizonte 5
Changsha 5
Dhaka 5
Falkenstein 5
Mexico City 5
Mountain View 5
Naples 5
Phoenix 5
Poplar 5
Rovato 5
Shenyang 5
Totale 3.224
Salva come PNG Salva come JPEG
Nome #
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 264
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab 254
CD8(+) T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI 240
T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. 239
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. 194
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. 174
Lambert-Eaton Myasthenic Syndrome associated with gastric schwannoma 169
Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral 169
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 166
Demyelinating Encephalomyeloradiculitis with Balò-like lesions 164
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 154
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 149
Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review 149
Increased CD4(+)CD25(+)Foxp3(+) T Cells in Peripheral Blood of Celiac Disease Patients: Correlation with Dietary Treatment. 148
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 148
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 148
Epidemiology of intensive care unit-acquired sepsis in Italy: Results of the SPIN-UTI network 134
Glioblastoma in multiple sclerosis: a case report 133
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 125
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 124
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 120
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 119
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 118
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 118
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 116
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 115
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 112
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 108
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 107
Fingolimod vs dimethyl fumarate in multiple sclerosis 105
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 97
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 96
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 96
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 89
Acyclovir-related kidney injury during alemtuzumab infusion 87
The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray) 85
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 84
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) 79
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 78
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 77
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 76
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 72
An early feasibility study for neurological devices: The ARCTRAN study 71
A true isolated cognitive relapse in multiple sclerosis 70
Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved 69
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 68
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 67
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study (Journal of Neurology, (2022), 269, 3, (1610-1617), 10.1007/s00415-021-10737-w) 63
Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome 62
An early feasibility study for neurological devices: The ARCTRAN study 44
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 35
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study 31
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice 18
Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications 17
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 5
Totale 6.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.461
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.461
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022381 35 16 19 41 13 11 8 55 22 23 54 84
2022/2023856 89 107 60 136 64 113 42 82 96 10 41 16
2023/2024405 18 93 14 20 18 68 35 12 7 20 42 58
2024/2025816 14 24 61 53 44 32 14 26 137 72 185 154
2025/20262.579 321 67 123 247 489 215 424 151 167 199 93 83
2026/202753 53 0 0 0 0 0 0 0 0 0 0 0
Totale 6.219